Point-of-care molecular diagnostics can provide efficient and cost-effective medical care, and they have the potential to fundamentally change our approach to global health. However, most existing approaches are not scalable to include multiple biomarkers. As a solution, we have combined commercial flat panel OLED display technology with protein microarray technology to enable high-density fluorescent, programmable, multiplexed biorecognition in a compact and disposable configuration with clinical-level sensitivity. Our approach leverages advances in commercial display technology to reduce pre-functionalized biosensor substrate costs to pennies per cm[superscript 2]. Here, we demonstrate quantitative detection of IgG antibodies to multiple viral antigens in patient serum samples with detection limits for human IgG in the 10 pg/mL range. We also demonstrate multiplexed detection of antibodies to the HPV16 proteins E2, E6, and E7, which are circulating biomarkers for cervical as well as head and neck cancers.
Details
- Application of Flat Panel OLED Display Technology for the Point-of-Care Detection of Circulating Cancer Biomarkers
- Katchman, Benjamin (Author)
- Smith, Joseph (Author)
- Obahiagbon, Uwadiae (Author)
- Kesiraju, Sailaja (Author)
- Lee, Yong Kyun (Author)
- O'Brien, Barry (Author)
- Kaftanoglu, Korhan (Author)
- Blain Christen, Jennifer (Author)
- Anderson, Karen (Author)
- Biodesign Institute (Contributor)
- Digital object identifier: 10.1038/srep29057
- Identifier TypeInternational standard serial numberIdentifier Value2045-2322
- The final version of this article, as published in Scientific Reports, can be viewed online at: https://www.nature.com/articles/srep29057
Citation and reuse
Cite this item
This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.
Katchman, B. A., Smith, J. T., Obahiagbon, U., Kesiraju, S., Lee, Y., O’Brien, B., . . . Anderson, K. S. (2016). Application of flat panel OLED display technology for the point-of-care detection of circulating cancer biomarkers. Scientific Reports, 6(1). doi:10.1038/srep29057